Odyssey Therapeutics Secures $213M Series D Financing to Advance Autoimmune Drug Pipeline Ahead of IPO

Boston, September 10 – Odyssey Therapeutics, a clinical-stage biopharmaceutical company dedicated to transforming the standard of care for patients with autoimmune and inflammatory diseases by developing precision medicines that target the underlying pathology of disease, today announced the completion of a $213 million Series D financing. In addition to the participation of all existing investors, new investors include Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations (LSI), and Wedbush Healthcare Partners. The proceeds will be used to support the development of Odyssey’s clinical and preclinical portfolio of drugs designed to precisely target drivers of complex autoimmune diseases.$218 million Series A financing in 2021, $168 million Series B financing in 2022, and in 2023$101 Million Series C Financing。This Series D financing brings the total capital raised since its establishment at the end of 2021 to 700 million US dollars.（$101 Million Series C Financing to Develop Next-Generation Precision Immunology and OncologyTumor New Drug；New Force! Completed $386 Million Financing in Less Than a Year to Develop Next-Generation Precision Immunology and Oncology Drugs）

Gary D. Glick, Ph.D., Founder and Chief Executive Officer of Odyssey Therapeutics, stated:"As we advance our programs toward significant clinical milestones, we are focused on translating our scientific efforts into meaningful benefits for patients. I am grateful for the continued support of our investors and their enthusiasm for our mission to deliver truly transformative medicines to patients suffering from inflammatory diseases."

OD-07656 is an orally administered small molecule RIPK2 inhibitor currently in Phase 1 clinical trials, with indications under development including UC and Crohn's disease. The preclinical pipeline includesOral small molecule IRAK4 inhibitor,OD-00910 is a monospecific tetravalent V-body designed to selectively agonize TNFR2 on Tregs, TSLP/IL-33 bispecific antibody, small molecule NLRP1 inhibitor, and small molecule MDA5 inhibitor.

In addition to this fundraising event, Shelley Chu, partner at Lightspeed VenturesPh.D., Paulina Hill, Partner at Sanofi Ventures, Nan Li, Founder and Managing Partner at Dimension Capital, Dr. Carolyn Ng, Partner at TPG Life Sciences Innovations (LSI), and Ksenija Pavletic, Partner and Chief Compliance Officer at Jeito Capital, will join.OdysseyThe Board of Directors.

OdysseyChairman of the Board Jeff Leiden, Ph.D., stated:"This financing demonstratesOdysseyWe are working hard to discover and provide important drugs to patients. I am delighted to welcome our new investors and work with our new board members, asOdyssey"Continuing to advance its programs through clinical development."

Since its establishment in 2021,OdysseyA comprehensive drug discovery and development capability has been established. The company has advanced an internally discovered program from conception to multiple clinical milestones, nominated several development candidate pipelines, and established multiple collaborations with pharmaceutical leaders and biotech innovators.